Medicare Open Enrollment Underway: 2027 Plan Changes, Cost Increases Noted
“People really need to do their research before they enroll in Medicare, because there are trade-offs,” said David Lipschutz, a co-director at the Center for Medicare Advocacy, NPR reported.
Annual Medicare Open Enrollment is underway, running through Dec. 7, bringing a complex set of choices, rising costs, and significant changes that go into effect in 2027 for roughly 70 million people.
During the enrollment period, beneficiaries can review and compare their current coverage, switch between Original Medicare and a Medicare Advantage Plan, change to a different Medicare Advantage Plan, or join or change a Medicare Part D prescription drug plan. Any changes made will take effect on Jan. 1, 2027. Those who are satisfied with their current coverage generally do not need to take any action.
Traditional Medicare consists of Parts A and B, covering hospital stays, skilled nursing care, doctor visits, outpatient care, and preventive screenings. Roughly half of beneficiaries are enrolled in traditional Medicare, while the other half opted for privately offered, all-in-one managed-care plans known as Medicare Advantage. About 4 million people are in Medicare Advantage plans that won’t be offered in 2027, and if they do nothing, they’ll be automatically enrolled in traditional Medicare.
Participants are bracing for a variety of upcoming adjustments to policy and expenses, including the expiration of temporary federal Part D premium assistance, new negotiations regarding drug pricing, and higher maximum out-of-pocket limits for Part D. The limit on yearly out-of-pocket costs for Medicare Part D medications will rise to $2,400, increasing from $2,100 in 2026, while the standard deductible will shift from $615 to $700.
A KFF study determined that individuals who maintain their current prescription drug coverage will experience an average 50% hike, moving from $34 to $51, with approximately 10.4 million people potentially facing increased premiums. Prices negotiated by Medicare will begin for 15 specific medications, including Ozempic, Rybelsus, Wegovy, Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo/Austedo XR, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet/Janumet XR, and Otezla.
“Higher healthcare costs are making it harder for older Americans to afford the care they need,” said Nancy LeaMond, AARP’s Executive Vice President and Chief Advocacy Officer.

Beneficiaries can review and compare coverage options or make adjustments during the open enrollment window by visiting Medicare.gov or calling 1-800-MEDICARE.
Those online tools allow individuals to apply for Medicare, check the status of a pending application, view proof of Medicare coverage, and update their personal contact information.
KFF acts as an independent source for health policy research, polling, and news, providing data-driven insights that clarify complex federal programs. Its Medicare 101 unit, authored by a team of policy experts in 2025, serves as a foundational resource for understanding the program’s structure, beneficiary demographics, and evolving financial mechanics.
By maintaining this comprehensive overview, KFF enables policymakers and the public to analyze how shifting regulations, such as those governing Part D prescription drug benefits and private plan payments, influence long-term healthcare access and affordability for the nation’s 68 million beneficiaries.
“It’s more important than ever to shop around, compare your options, and choose the coverage that’s best for you,” she said.